Marizomib

From WikiMD.org
Jump to navigation Jump to search

Marizomib

Marizomib (pronunciation: /məˈrɪzoʊmɪb/) is a proteasome inhibitor used in the treatment of multiple myeloma. It is a beta-lactone-gamma-lactam compound that irreversibly binds to the proteasome and inhibits its function.

Etymology

The name "Marizomib" is derived from the genus Marizomus, a type of marine bacteria from which the drug was originally isolated. The suffix "-ib" is commonly used in the names of small molecule inhibitors.

Pharmacology

Marizomib inhibits the chymotrypsin-like activity of the 20S proteasome, a large protein complex that degrades unneeded or damaged proteins in the cell. By blocking the proteasome, marizomib disrupts the balance of proteins in the cell, leading to cell death.

Clinical Use

Marizomib is currently being investigated in clinical trials for the treatment of multiple myeloma and other malignant diseases. It has shown promise in preclinical studies for its ability to cross the blood-brain barrier, suggesting potential use in the treatment of brain tumors.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski